Home » Topics » BioWorld Science

BioWorld Science
RSS

Vifor prepares to begin phase I trial of oral ferroportin inhibitor VIT-2763

Feb. 9, 2018

Implantable device allows photodynamic therapy for tumors deep in the body

Feb. 9, 2018

GlaxoSmithKline reviews milestones of fourth quarter 2017

Feb. 9, 2018

SPK-8011 shown safe and effective for hemophilia A

Feb. 9, 2018

AstraZeneca announces pipeline highlights of fourth quarter 2017

Feb. 9, 2018

ABAC Therapeutics identifies novel antibacterials

Feb. 9, 2018

Therapix Biosciences clarifies regulatory pathway for THX-110

Feb. 9, 2018

Novel ACKR3 antagonists patented by Idorsia Pharmaceuticals

Feb. 9, 2018

Shanghai Yingli Pharmaceutical presents new TGF-beta receptor type-1 inhibitors

Feb. 9, 2018

Roche discovers new serine protease HTRA1 inhibitors

Feb. 9, 2018

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 14, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 13, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...